Autolus Therapeutics (AUTL) Competitors

Autolus Therapeutics logo
$1.09 -0.05 (-4.39%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.12 +0.03 (+3.21%)
As of 05:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AUTL vs. KARD, TSHA, ANAB, DMRA, and ALVO

Should you buy Autolus Therapeutics stock or one of its competitors? Autolus Therapeutics's main competitors and comparable companies include Kardigan (KARD), Taysha Gene Therapies (TSHA), AnaptysBio (ANAB), Damora Therapeutics, Inc. Common Stock (DMRA), and Alvotech (ALVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Autolus Therapeutics compare to Kardigan?

Kardigan (NASDAQ:KARD) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Kardigan has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -186.37%. Kardigan's return on equity of -152.99% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
KardiganN/A -152.99% -46.19%
Autolus Therapeutics -186.37%-263.25%-48.04%

Kardigan has higher earnings, but lower revenue than Autolus Therapeutics. Kardigan is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
KardiganN/AN/A-$191.94M-$2.88N/A
Autolus Therapeutics$75.39M3.85-$287.53M-$0.97N/A

In the previous week, Kardigan had 13 more articles in the media than Autolus Therapeutics. MarketBeat recorded 19 mentions for Kardigan and 6 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.57 beat Kardigan's score of 0.21 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kardigan
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Autolus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kardigan presently has a consensus target price of $41.00, indicating a potential upside of 210.84%. Autolus Therapeutics has a consensus target price of $10.00, indicating a potential upside of 817.43%. Given Autolus Therapeutics' higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Kardigan.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88

Summary

Kardigan beats Autolus Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Autolus Therapeutics compare to Taysha Gene Therapies?

Autolus Therapeutics (NASDAQ:AUTL) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Autolus Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -186.37%. Taysha Gene Therapies' return on equity of -51.87% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Autolus Therapeutics-186.37% -263.25% -48.04%
Taysha Gene Therapies N/A -51.87%-40.29%

Autolus Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 817.43%. Taysha Gene Therapies has a consensus price target of $12.75, suggesting a potential upside of 218.75%. Given Autolus Therapeutics' higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Taysha Gene Therapies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
Taysha Gene Therapies
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

Taysha Gene Therapies has lower revenue, but higher earnings than Autolus Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autolus Therapeutics$75.39M3.85-$287.53M-$0.97N/A
Taysha Gene Therapies$9.77M133.49-$109M-$0.43N/A

In the previous week, Taysha Gene Therapies had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 10 mentions for Taysha Gene Therapies and 6 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.57 beat Taysha Gene Therapies' score of 0.31 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Autolus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Taysha Gene Therapies
0 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Taysha Gene Therapies beats Autolus Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to AnaptysBio?

Autolus Therapeutics (NASDAQ:AUTL) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

AnaptysBio has a net margin of 96.30% compared to Autolus Therapeutics' net margin of -186.37%. AnaptysBio's return on equity of -17.54% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Autolus Therapeutics-186.37% -263.25% -48.04%
AnaptysBio 96.30%-17.54%-1.08%

Autolus Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

In the previous week, AnaptysBio had 6 more articles in the media than Autolus Therapeutics. MarketBeat recorded 12 mentions for AnaptysBio and 6 mentions for Autolus Therapeutics. AnaptysBio's average media sentiment score of 0.79 beat Autolus Therapeutics' score of 0.57 indicating that AnaptysBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Autolus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AnaptysBio
4 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AnaptysBio has higher revenue and earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autolus Therapeutics$75.39M3.85-$287.53M-$0.97N/A
AnaptysBio$234.60M5.78-$13.23M$4.969.20

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 31.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Autolus Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 817.43%. AnaptysBio has a consensus price target of $75.67, suggesting a potential upside of 65.90%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Autolus Therapeutics is more favorable than AnaptysBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
AnaptysBio
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69

Summary

AnaptysBio beats Autolus Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Autolus Therapeutics (NASDAQ:AUTL) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Autolus Therapeutics had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Autolus Therapeutics and 5 mentions for Damora Therapeutics, Inc. Common Stock. Autolus Therapeutics' average media sentiment score of 0.57 beat Damora Therapeutics, Inc. Common Stock's score of 0.38 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Autolus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Damora Therapeutics, Inc. Common Stock
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than Autolus Therapeutics. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autolus Therapeutics$75.39M3.85-$287.53M-$0.97N/A
Damora Therapeutics, Inc. Common StockN/AN/A-$209.84M-$1.41N/A

Autolus Therapeutics has a beta of 2.32, suggesting that its share price is 132% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -186.37%. Damora Therapeutics, Inc. Common Stock's return on equity of -122.16% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Autolus Therapeutics-186.37% -263.25% -48.04%
Damora Therapeutics, Inc. Common Stock N/A -122.16%-62.32%

Autolus Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 817.43%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $46.38, suggesting a potential upside of 105.56%. Given Autolus Therapeutics' higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
Damora Therapeutics, Inc. Common Stock
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.00

Summary

Autolus Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Alvotech?

Autolus Therapeutics (NASDAQ:AUTL) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Autolus Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 817.43%. Alvotech has a consensus price target of $8.40, suggesting a potential upside of 92.22%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43

Alvotech has higher revenue and earnings than Autolus Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autolus Therapeutics$75.39M3.85-$287.53M-$0.97N/A
Alvotech$588.90M2.24$27.92M-$0.82N/A

Alvotech has a net margin of -50.62% compared to Autolus Therapeutics' net margin of -186.37%. Alvotech's return on equity of 0.00% beat Autolus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Autolus Therapeutics-186.37% -263.25% -48.04%
Alvotech -50.62%N/A -11.71%

Autolus Therapeutics has a beta of 2.32, meaning that its share price is 132% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alvotech had 17 more articles in the media than Autolus Therapeutics. MarketBeat recorded 23 mentions for Alvotech and 6 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.57 beat Alvotech's score of 0.19 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Autolus Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
5 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Autolus Therapeutics beats Alvotech on 9 of the 17 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AUTL vs. The Competition

MetricAutolus TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$303.63M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-1.1226.6634.2628.24
Price / Sales3.8515.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book10.904.184.463.72
Net Income-$287.53M-$24.15M$3.52B$393.10M
7 Day Performance-11.74%-7.78%-5.92%-5.76%
1 Month Performance-31.88%-5.96%-4.58%-7.14%
1 Year Performance-15.50%-8.08%-1.93%-7.46%

Autolus Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AUTL
Autolus Therapeutics
3.4898 of 5 stars
$1.09
-4.4%
$10.00
+817.4%
-18.7%$303.63M$75.39MN/A752
KARD
Kardigan
2.6094 of 5 stars
$15.18
-2.2%
$41.13
+170.9%
N/A$1.45BN/AN/A241
TSHA
Taysha Gene Therapies
2.0675 of 5 stars
$4.37
+0.9%
$12.77
+192.2%
-2.9%$1.42B$9.77MN/A99
ANAB
AnaptysBio
3.1192 of 5 stars
$47.97
+3.3%
$75.67
+57.7%
+31.2%$1.42B$234.60M316.73104
DMRA
Damora Therapeutics, Inc. Common Stock
3.3011 of 5 stars
$24.07
+1.6%
$46.38
+92.7%
-1.3%$1.42BN/AN/A40

Related Companies and Tools


This page (NASDAQ:AUTL) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners